Filing Details
- Accession Number:
- 0001104659-16-131270
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-07-06 16:15:30
- Reporting Period:
- 2016-07-01
- Filing Date:
- 2016-07-06
- Accepted Time:
- 2016-07-06 16:15:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1626199 | Nivalis Therapeutics Inc. | NVLS | Pharmaceutical Preparations (2834) | 208969493 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1672659 | Malcom David Rodman | C/O Nivalis Therapeutics, Inc. 3122 Sterling Circle, Suite 200 Boulder CO 80301 | Exec Vice President And Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-07-01 | 18,055 | $0.00 | 18,055 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-07-05 | 5,950 | $4.66 | 12,105 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2016-07-01 | 18,055 | $0.00 | 18,055 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
198,612 | No | 4 | M | Direct |
Footnotes
- Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's.
- Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.57 to $4.78, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
- Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016.